PLoS ONE (Jan 2018)

Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy.

  • Josivan Gomes Lima,
  • Lucia Helena C Nobrega,
  • Natalia Nobrega Lima,
  • Marcel Catão Ferreira Dos Santos,
  • Pedro Henrique Dantas Silva,
  • Maria de Fatima P Baracho,
  • Debora Nobrega Lima,
  • Julliane Tamara Araújo de Melo Campos,
  • Leonardo Capistrano Ferreira,
  • Francisco Paulo Freire Neto,
  • Carolina de O Mendes-Aguiar,
  • Selma Maria B Jeronimo

DOI
https://doi.org/10.1371/journal.pone.0199052
Journal volume & issue
Vol. 13, no. 6
p. e0199052

Abstract

Read online

INTRODUCTION:Berardinelli-Seip Congenital Lipodystrophy (BSCL) is a rare autosomal recessive disease that affects the development of adipocytes and leads to an inability to store fat in adipocytes. This study aimed to evaluate the life expectancy and the causes of death of patients with BSCL. METHOD:We analyzed death certificates, and medical records of BSCL patients who died between 1997 and 2017. If the death certificate was incomplete or unavailable, we reviewed the medical records, and if they were not available too, we collected information from the patient's relatives to understand how the death happened. We calculated the potential years of life lost as a result of premature death. RESULTS:Twenty patients (12 female and 8 male) died between 1997 and 2017. The mean age at the time of death was 27.1±12.4 years (women 25.2±12.5 vs. men 29.9±12.6 years, p = 0.41). Life expectancy for the study population was 62.9±4.8 years. The potential number of years of life lost was 35.6±16.6 years. The causes of deaths were divided into three major groups: infections (7 patients, 35%), liver disease (7 patients, 35%), and other causes (acute pancreatitis, one patient; renal failure, three patients; sudden death/myocardial infarction, two patients). Three patients had pulmonary fibrosis. CONCLUSION:BSCL led to premature death, cutting the patients' lifespan by 30 or more years. The majority of these young patients died of liver disease or infection. Other studies are needed to understand better the mechanisms that predispose to infections, as well as to assess whether new therapies can alter the natural history of this disease.